Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B

Soon Woo Nam; Si Hyun Bae; Seung Woo Lee; Yeon Soo Kim; Sang Bum Kang; Jong Young Choi; Se Hyun Cho; Seung Kew Yoon; Joon-Yeol Han; Jin Mo Yang; Young Suk Lee; Reshetnyak, Vasiliy I.
March 2008
World Journal of Gastroenterology;3/21/2008, Vol. 14 Issue 11, p1781
Academic Journal
AIM: To evaluate the efficacy of short-term overlap lamivudine therapy with adefovir in patients with lamivudine-resistant and naïve chronic hepatitis B, we compared patients receiving overlap therapy with those receiving adefovir alone. METHODS: Eighty patients who had received lamivudine treatment for various periods and had a lamivudine-resistant liver function abnormality were enrolled. Forty of these patients received adefovir treatment combined with lamivudine treatment for ≥ 2 mo, while the other 40 received adefovir alone. We assessed the levels of hepatitis B virus (HBV) DNA at 0, 12 and 48 wk and serum alanine aminotransferase (ALT) levels after 0, 12, 24 and 48 wk of adefovir treatment in each group. RESULTS: We found serum ALT became normalized in 72 (87.5%) of the 80 patients, and HBV DNA decreased by ≥ 2 log10 copies/mL in 60 (75%) of the 80 patients at the end of a 48-wk treatment. HBV DNA levels were not significantly different between the groups. The improvements in serum ALT were also not significantly different between the two groups. CONCLUSION: These findings suggest short-term overlap lamivudine treatment results in no better virological and biological outcomes than non-overlap adefovir monotherapy.


Related Articles

  • Expression of stable hepatitis B viral polymerase associated with GRP94 in E. coli. Kim, S. S.; Shin, H. J.; Cho, Y. H.; Rho, H. M. // Archives of Virology;Jul2000, Vol. 145 Issue 7, p1305 

    Summary. We here presented evidence that a 94-kDa glucose-regulated protein (GRP94) was associated with hepatitis B viral (HBV) polymerase in the human liver cell HepG2 and this association could be applied even in Escherichia coli. We investigated the role of GRP94 in the expression and...

  • The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. Kim, Moon-Chan; Jung, Seok; Shin, Jung; Park, Neung; Jung, Seok Won; Shin, Jung Woo; Park, Neung Hwa // Digestive Diseases & Sciences;Apr2011, Vol. 56 Issue 4, p1215 

    Background and Aims: The aim of this study was to determine the optimal time and HBV DNA levels during the treatment period for prediction of virological breakthrough (VBT) 3 years after adefovir monotherapy in chronic hepatitis B (CHB) patients with lamivudine...

  • Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases. Bloom, Kristie; Ely, Abdullah; Mussolino, Claudio; Cathomen, Toni; Arbuthnot, Patrick // Molecular Therapy;Oct2013, Vol. 21 Issue 10, p1889 

    Chronic hepatitis B virus (HBV) infection remains an important global health problem. Stability of the episomal covalently closed circular HBV DNA (cccDNA) is largely responsible for the modest curative efficacy of available therapy. Since licensed anti-HBV drugs have a post-transcriptional...

  • HBV DRUG RESISTANCE: ITS RELEVANCE IN CLINICAL PRACTICE. Hazam, Rajib Kishore; Kar, Premashis // Hepatitis B Annual;2007, Vol. 4, p24 

    Drug resistance can be considered as a natural response to the selective pressure of the drug. An increase in HBV DNA can be a good indicator of the presence of a resistant HBV mutant population. The nucleoside analogues Lamivudine, Adefovir, Entecavir etc. are oral drugs used for Hepatitis B...

  • Hepatitis B virus escape mutants induced by antiviral therapy. Julie Sheldon; Vincent Soriano // Journal of Antimicrobial Chemotherapy (JAC);Apr2008, Vol. 61 Issue 4, p766 

    The hepatitis B virus (HBV) polymerase and envelope genes overlap in such a way that resistance mutations to antiviral agents in the reverse transcriptase gene may affect the antigenicity of the HBV surface antigen. Mutant viruses may escape serological diagnosis using specific anti-HBV surface...

  • Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Whittle, Hilton; Jaffar, Shabbar; Wansbrough, Michael; Mendy, Maimuna; Dumpis,, Uga; Collinson, Andrew; Hall, Andrew // BMJ: British Medical Journal (International Edition);9/14/2002, Vol. 325 Issue 7364, p569 

    Abstract Objective: To determine the duration of protection from hepatitis B vaccine given in infancy and early childhood. Design: Cross sectional serological study of hepatitis B virus infection in children of various ages 14 years after the start of a trial of vaccination regimens. Setting:...

  • Use of rituximab in pemphigus patients with chronic viral hepatitis: Report of three cases. Kanwar, Amrinder J.; Vinay, Keshavamurthy; Heelan, Kara; Walsh, Scott; Shear, Neil H.; Dhiman, Radha K. // Indian Journal of Dermatology, Venereology & Leprology;Sep/Oct2014, Vol. 80 Issue 5, p422 

    Use of rituximab in patients with chronic viral hepatitis can worsen pre-existing hepatitis or reactivate occult infection. There are no reports of use of rituximab in pemphigus patients with co-existing viral hepatitis. Herein, we report three pemphigus patients with co-existing chronic viral...

  • Chronic viral hepatitis B and C: What you need to know in 1995.  // Modern Medicine;Apr95, Vol. 63 Issue 4, p29 

    Presents Willis C. Maddrey's tips for the treatment of chronic viral hepatitis B and C. Chronicity of hepatitis C; Use of interferon alfa-2b in treating hepatitis; Use of ursodiol for treatment failures; Antigens associated with hepatitis.

  • Tenofovir does well in chronic hepatitis B treatment comparison.  // PharmacoEconomics & Outcomes News;12/12/2009, Issue 593, p9 

    The article discusses research on the cost effectiveness of tenofovir in treating chronic hepatitis B in Taiwan. It references the study "Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B," by M. Buti and colleagues, published in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics